American Express Co vs ResMed Inc. — how do they compare? American Express Co trades at $341.44 (market cap $230.15B), while ResMed Inc. trades at $224.81 (market cap $32.61B). The key difference: American Express Co is far larger — about 7.1× ResMed Inc.'s market cap, and ResMed Inc. pays the higher dividend (1.17%). Which is the better fit depends on your goals.
| AXP | RMD | |
|---|---|---|
Market Cap | $230.15B | $32.61B |
Sector | Financials | Health |
52-Week High | $384.82 | $293.73 |
52-Week Low | $292.27 | $182.82 |
Dividend Yield | 1.11% | 1.17% |
Enterprise Value | — | $31.97B |
Signals from Pluang's Aura AI — not financial advice
AXP trades at $341.25, up 0.7% on the day, with a bullish technical signal and strong support at $339. Revenue grew to $72.23B in 2025, with net income of $10.83B and a 15.07% net margin. Recent earnings beat expectations in Q1 and Q2 2026, while analyst consensus is a Buy with a $369.42 price target. News highlights Amex Ventures' AI investments and premium cardmember perks.
Outlook is positive given earnings momentum and strategic AI bets, but risks include rising debt levels and competitive pressure. The stock offers growth potential with a reasonable P/E of 20.68, though investors should watch for economic sensitivity in consumer spending.
ResMed (RMD) trades at $221.22, up 0.53% with a bullish technical signal and strong fundamental performance. The company delivered four consecutive quarterly earnings beats, with Q4 2026 EPS of $2.95 beating expectations by 2.1%. Revenue grew 9% year-over-year to $1.5 billion, while maintaining robust profitability with 61.1% gross margins and 26.9% net income margins. Recent strategic moves include the $490 million sale of MatrixCare to focus on core sleep and respiratory care markets.
The stock presents a compelling growth story with consistent execution, though near-term headwinds from weak 2027 revenue guidance create uncertainty. Analyst consensus targets $235.00 (6.2% upside) with 40% buy ratings. Key risks include ventilator sales suspension, cost pressures, and competitive threats in the medical device space. The company's strong cash flow generation and shareholder returns ($1.0 billion in 2026) support long-term value creation.
Trailing returns across standard periods
Latest headlines on both assets
American Express Company is a global payment and travel company. The Company's principal products and services are charge and credit payment card products and travel-related services offered to consumers and businesses around the world.
Read more on AXP →ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →